- Trial phase
- Preclinical (IND-enabling)
- Time to market
- RC298 is in IND-enabling (preclinical) development. An IND submission in China is expected in H1 2027. If clinical development proceeds, an approved product would likely be several years away, assuming successful Phase 1, 2, and 3 trials.
- Why 4/10
- RC298 is a preclinical (IND-enabling) asset with no clinical trials yet; the next catalyst is an IND submission in China expected in H1 2027, roughly 6-8 months away, but this is a non-binary regulatory step for a pipeline-expansion asset that is not the company's primary value driver (telitacicept is). The deal was already announced and priced in on Nov 12, 2026.
Watch for the IND submission for RC298 in China expected H1 2027. Near-term stock movement will likely come from telitacicept Phase 3 readouts (UPSTREAM MG and SjD topline data expected 1H 2027), not RC298. The deal's upfront cost ($10M cash + ~$46M in warrants) and potential future dilution from the $150M ATM facility create an overhang to monitor.
Price Chart
Executive Summary
RC298 is a preclinical, next-generation, long-acting dual BAFF/APRIL inhibitor that Vor Biopharma licensed from RemeGen on November 12, 2026, for ex-Greater China rights. Vor Bio paid $10M in cash plus a pre-funded warrant for 2.3M shares (valued at ~$46M) upfront, with up to $300M in potential development milestones. The drug is in IND-enabling development, with an IND submission in China expected in H1 2027. RC298 is a pipeline-expansion asset; Vor Bio's primary value driver is telitacicept (a first-generation BAFF/APRIL inhibitor in Phase 3 for multiple autoimmune indications). For a non-medical investor, RC298 is an early-stage speculative addition to an existing franchise, not a near-term binary catalyst. Vor Biopharma (VOR) trades on Nasdaq at ~$19.42 with a market cap of roughly $1.23B, carries a Strong Buy analyst consensus (mean target $39), and has cash runway into early 2029.
How It Works
RC298 is a dual BAFF/APRIL inhibitor, meaning it blocks two immune-signaling proteins (BAFF and APRIL) that are overactive in autoimmune diseases. By neutralizing both targets, the drug aims to reduce the production of self-attacking antibodies while sparing broader immune function. RC298 is designed as a long-acting, next-generation version with higher potency and a longer half-life, which could mean less frequent dosing than the first-generation drug telitacicept.
Trial Status
RC298 has not yet entered clinical trials. It is in IND-enabling development, with the company targeting an IND submission in China in the first half of 2027. Preclinical data on potency and half-life were cited as encouraging by the company but have not been publicly disclosed in detail.
The Two-Sided Case
Upcoming Catalysts
- IND submission for RC298 in China expected H1 2027
- Telitacicept Phase 3 UPSTREAM MG (myasthenia gravis) topline data expected 1H 2027 (separate asset but same franchise and company)
- Telitacicept Phase 3 UPSTREAM SjD (Sjögren's disease) topline data expected 1H 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vor Biopharma Inc. 8-K VOR ·Originating report